Related Experiment Video

Updated: Mar 22, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.2K

Somatostatin Analog Therapy in Small Cell Lung Cancer

Alfredo Tartarone1, Rosa Lerose2, Michele Aieta1

  • 1Unit of Medical Oncology, Department of Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, PZ, Italy.

Seminars in Nuclear Medicine
|April 13, 2016
PubMed

Insights

Standard chemotherapy for small cell lung cancer (SCLC) shows limited survival benefits. This review explores the potential of somatostatin (SST) analogs, targeting neuroendocrine markers in SCLC, for improved treatment outcomes.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Standard chemotherapy for small cell lung cancer (SCLC) has plateaued in efficacy.
  • SCLC tumors express neuroendocrine markers, including somatostatin (SST) receptors.
  • Current SCLC treatments yield disappointing survival rates.

Purpose of the Study:

  • To review the potential therapeutic role of somatostatin (SST) analogs in small cell lung cancer (SCLC).
  • To evaluate the use of SST analogs and radiolabeled SST analogs for SCLC treatment.

Main Methods:

  • Literature review focusing on studies investigating somatostatin (SST) analogs in SCLC.
  • Analysis of research on neuroendocrine markers in SCLC and their therapeutic targeting.
  • Examination of clinical data on SST analog efficacy in SCLC patients.

Main Results:

  • SCLC exhibits expression of neuroendocrine markers, notably somatostatin (SST) receptors.
  • SST analogs and radiolabeled SST analogs are being investigated for SCLC treatment.
  • The review synthesizes current evidence on the role of SST analogs in SCLC therapy.

Conclusions:

  • Somatostatin (SST) analogs represent a promising therapeutic avenue for SCLC.
  • Targeting SST receptors in SCLC may overcome limitations of standard chemotherapy.
  • Further research into SST analog-based therapies is warranted for SCLC patients.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K